41653-72-9 Purity
98%
If you have any other questions or need other size, please get a quote.
Specification
Gao, Aijia, et al. Dalton Transactions 51.6 (2022): 2567-2576.
Successful development of heterogeneous catalysts for epoxide cycloaddition reactions with carbon dioxide remains essential to recycle CO2 and reach carbon neutrality. The study engineered and synthesized Zr-based MOFs by combining different molar ratios of 4-guanidinobenzoic acid (Gua) with 1,4-benzenedicarboxylic acid (BDC) to introduce functional guanidyl groups into their structure. The researchers developed a small Zr-MOF measuring approximately 350 nm by adding Gua in a 20% molar ratio which resulted in UiO-66-Gua0.2(s).
The UiO-66-Gua0.2(s) Zr-MOF displayed superior catalytic performance for epoxide cycloaddition to CO2 when assisted by Bu4NBr cocatalyst and achieved a 97% yield of chloropropene carbonate under conditions of 90 °C and 1 atm CO2 pressure compared to larger Zr-MOFs with diverse guanidyl compositions.
The top performance of UiO-66-Gua0.2(s) stems from the combined effects of guanidyl groups functioning as hydrogen-bond donors and Zr centers operating as Lewis acid sites. The heterogeneous catalyst demonstrated outstanding performance in transforming various epoxides while successfully being reused for five subsequent cycles without major losses in activity.
Dong, Shengting, et al. ACS nano, 2025, 19(2), 2742-2758.
In idiopathic pulmonary fibrosis (IPF), interleukin 11 (IL-11) plays a crucial role by promoting the conversion of fibroblasts into myofibroblasts, thereby accelerating the disease's progression. In response, this work developed a novel inhalable small interfering RNA (siRNA) delivery system called PEI-GBZA, which effectively loads siIL-11 to target IL-11.
Design and Preparation
Researchers developed PEI-GBZA by chemically modifying low-molecular-weight polyethylenimine (PEI) with 4-guanidinobenzoic acid (GBZA). Modifications to PEI-GBZA facilitate siIL-11 encapsulation using hydrophobic forces, hydrogen bonds and electrostatic interactions to produce stable nanoparticles (PEI-GBZA/siIL-11 NPs).
Action Mechanism and Effect
The system functions to block fibroblast conversion into myofibroblasts and epithelial-mesenchymal transition (EMT) while reducing neutrophil and macrophage recruitment to decrease existing fibrotic lesions in an IPF model. When inhaled they remain trapped in fibrotic lesions which results in remarkable disease progression improvements within a bleomycin-induced pulmonary fibrosis model.
This inhalation therapy presents minimal systemic toxicity. This noninvasive RNA delivery platform demonstrates significant potential for respiratory disease management while providing promising treatment prospects for IPF and possibly other pulmonary disorders.
The molecular formula is C8H10ClN3O2.
The synonyms are N-(4-Carboxyphenyl)guanidine hydrochloride, 4-Guanidinobenzoic acid HCl, 4-guanidinobenzoic acid hydrochloride salt.
The molecular weight is 215.64 g/mol.
The parent compound is 4-Guanidinobenzoic acid.
The structure can be viewed at [link]
The IUPAC name is 4-(diaminomethylideneamino)benzoic acid;hydrochloride.
The InChI is InChI=1S/C8H9N3O2.ClH/c9-8(10)11-6-3-1-5(2-4-6)7(12)13;/h1-4H,(H,12,13)(H4,9,10,11);1H.
The InChIKey is YETFLAUJROGBMC-UHFFFAOYSA-N.
The CAS number is 42823-46-1.
The hydrogen bond donor count is 4.
Reference: [1] Patent: US2010/29638, 2010, A1, . Location in patent: Page/Page column 62
Reference: [1] Patent: CN106543041, 2017, A, . Location in patent: Paragraph 0023-0037
Reference: [1] European Journal of Organic Chemistry, 2014, vol. 2014, # 17, p. 3565 - 3569
Reference: [1]Journal of Medicinal Chemistry,1986,vol. 29,p. 514 - 519
Reference: [1]Journal of Medicinal Chemistry,1986,vol. 29,p. 514 - 519
Reference: [1]Journal of Medicinal Chemistry,1986,vol. 29,p. 514 - 519
* For details of the synthesis route, please refer to the original source to ensure accuracy.
Please kindly note that our products are for research use only.
Download